B-cell receptor specific for Mucin-4 epitopes (BCR-MUC4)

B-cell receptors specific for MUC4 epitopes are membrane-bound immunoglobulins on B-lymphocytes that recognize specific segments of the Mucin-4 (MUC4) glycoprotein (PMID: 21533181). MUC4 is a large transmembrane mucin that is aberrantly overexpressed in several cancers, most notably pancreatic ductal adenocarcinoma (PDAC), where it serves as a diagnostic marker and a driver of malignancy (PMID: 15150570). These receptors are critical in the development of humoral immunity, as their engagement by MUC4-derived antigens leads to the production of antibodies that can inhibit tumor growth and metastasis (PMID: 28603436). In therapeutic strategies, such as B-cell epitope-based vaccines, these BCRs are targeted to induce a polyclonal antibody response against the tandem repeat or other extracellular domains of MUC4 (PMID: 21143405). The resulting antibodies can interfere with the MUC4-ErbB2 signaling complex, which is known to promote cell proliferation and survival in cancer cells (PMID: 17255261). However, because MUC4 is also expressed at lower levels in normal tissues like the respiratory tract and ocular surface, targeting these receptors carries a theoretical risk of autoimmune reactions (PMID: 11059871).

Other names

MUC4-specific B-cell receptorAnti-MUC4 B-cell receptorMucin-4 specific BCR

Vaccine-mediated activation of B-cell receptors leads to the production of high-affinity antibodies against MUC4-expressing tumor cells, which can then mediate antibody-dependent cellular cytotoxicity (ADCC) and inhibit oncogenic signaling pathways such as the MUC4-ErbB2 complex.